文献速递中枢神经肿瘤放疗放疗物理与技术

海马保护性VMAT放疗原发脑肿瘤的剂量学与神经认知功能评估

Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment.
PubMed 文献 · Radiat Oncol · 2018-02-20

本研究回顾性分析2014年2月至2015年12月接受海马保护性VMAT脑放疗的原发脑肿瘤患者,对侧海马优化标准为Dmax<17 Gy。26例患者放疗后7个月完成神经认知功能测试,SVLT-TR、SVLT-DR、SVLT-Recognition平均相对变化分别为-7.7%、-9.2%、-3.4%。结论认为VMAT可有效保护对侧海马以保留言语记忆功能。

要点

  • 对侧海马Dmax优化标准为<17 Gy,中位Dmax为16.4 Gy。
  • 放疗后7个月SVLT-TR、SVLT-DR、SVLT-Recognition平均相对变化分别为-7.7%、-9.2%、-3.4%。
  • 左海马及双侧海马平均剂量在SVLT-TR和SVLT-Recognition恶化患者中显著更高。

核心结论

  • VMAT可有效保护原发脑肿瘤患者对侧海马以保留言语记忆功能。
  • 需进一步研究确定最可能从海马保护性放疗中获益的患者。

研究设计与样本

  • 回顾性研究,纳入2014年2月至2015年12月接受海马保护性VMAT脑放疗的原发脑肿瘤患者。
  • 对侧海马优化标准为Dmax<17 Gy。
  • 26例患者在基线及放疗后7个月完成SVLT-TR、SVLT-DR和SVLT-Recognition测试。

主要发现

  • 26例患者中位年龄49.5岁(范围26-77岁),14例(53.8%)为III/IV级肿瘤。
  • 对侧海马中位Dmax为16.4 Gy(范围3.5-63.4),中位平均剂量EQD2/2为7.4 Gy2(范围0.7-13.1)。
  • 放疗后7个月SVLT-TR、SVLT-DR、SVLT-Recognition平均相对变化分别为-7.7%(95%CI -19.6%至4.2%)、-9.2%(95%CI -25.4%至7.0%)、-3.4%(95%CI -12.7%至5.8%)。
  • 2例(7.7%)SVLT-TR和SVLT-DR恶化,3例(11.5%)SVLT-Recognition恶化。
  • 左海马和双侧海马平均剂量在SVLT-TR和SVLT-Recognition恶化患者中显著高于未恶化者。

关键数值与推荐

  • 对侧海马优化标准为最大剂量(Dmax)<17 Gy。

临床怎么用

  • 原发脑肿瘤VMAT放疗中可按对侧海马Dmax<17 Gy进行优化以保护言语记忆功能。
  • 左海马及双侧海马平均剂量较高者可能更易出现言语记忆功能恶化,计划时应关注。

局限性

  • 回顾性研究,样本量26例。
  • 神经认知功能仅评估至放疗后7个月。
  • 需进一步研究确定最可能获益的患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We hypothesized that hippocampal-sparing radiotherapy via volumetric modulated arc therapy (VMAT) could preserve the neurocognitive function (NCF) of patients with primary brain tumors treated with radiotherapy. METHODS: We reviewed data from patients with primary brain tumors who underwent hippocampal-sparing brain radiotherapy via VMAT between February 2014 and December 2015. The optimization criteria for the contralateral hippocampus was a maximum dose (Dmax) of less than 17 Gy. For NCF evaluations, the Seoul Verbal Learning Test for total recall, delayed recall, and recognition (SVLT-TR, DR, and Recognition) was performed at baseline and at seven months after radiotherapy. RESULTS: A total of 26 patients underwent NCF testing seven months after radiotherapy. Their median age was 49.5 years (range 26-77 years), and 14 (53.8%) had grade III/IV tumors. The median Dmax to the contralateral hippocampus was 16.4 Gy (range 3.5-63.4). The median mean dose to the contralateral hippocampus, expressed as equivalent to a 2-Gy dose (EQD2/2), was 7.4 Gy2 (0.7-13.1). The mean relative changes in SVLT-TR, SVLT-DR, and SVLT-Recognition at seven months compared to the baseline were - 7.7% (95% confidence interval [CI], - 19.6% to 4.2%), - 9.2% (95% CI, - 25.4% to 7.0%), and - 3.4% (- 12.7% to 5.8%), respectively. Two patients (7.7%) showed deteriorated NCF in the SVLT-TR and SVLT-DR, and three (11.5%) in the SVLT-Recognition. The mean dose of the left hippocampus and bilateral hippocampi were significantly higher in patients showing deterioration of the SVLT-TR and SVLT-Recognition than in those without deterioration. CONCLUSIONS: The contralateral hippocampus could be effectively spared in patients with primary brain tumor via VMAT to preserve the verbal memory function. Further investigation is needed to identify those patients who will most benefit from hippocampal-sparing radiotherapy of the primary brain tumor.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim KS, Wee CW, Seok JY, et al. Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment. Radiat Oncol. 2018. PMID: 29463267. doi:10.1186/s13014-018-0975-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。